Thomas Siepmann

Thomas Siepmann Ph.D.

Washington, DC Phone: (703) 917-0000 ext 209 Fax: (703) 997-4905

Dr. Siepmann provides legal counseling services relating to the procurement of patent rights through patent prosecution and negotiation of intellectual property licensing agreements. With over twelve years of legal experience, Dr. Siepmann focuses his practice on the areas of patent preparation and prosecution, validity and infringement opinions, and intellectual property licensing. Dr. Siepmann’s technical experience includes a doctorate in biochemistry and post-doctoral studies in organic synthetic chemistry, where his studies included biochemistry techniques, organic synthetic chemistry, molecular biology, cloning, and analytical chemistry techniques. He is experienced in molecular biology technologies including therapeutic antibodies, vaccines, immunochemistry, nucleic acid sequencing, nucleic acid amplification and detection, biologics, fermentation and cell culture methods, enzymes and protein chemistry, medical devices, as well as chemical technologies including amphiphilic molecules and detergents, terpenes, nucleic acid analogs, silica-based chemistry, photochemistry, photolithography, nanoparticle technologies, process chemistry, and pharmaceutical chemistry.

Before joining MH2 Technology Law Group, LLP, Dr. Siepmann was a partner at LeClairRyan, LLP. Dr. Siepmann has served as the Director, Intellectual Property for the biotechnology company Affymetrix, Inc. (acquired in 2016 by Thermo Fisher Scientific). He was also Counsel at Thompson Coburn, as well as an associate attorney at Birch, Stewart, Kolasch and Birch, LLP.

Bar Admissions:

  • Utah
  • District of Columbia
  • Registered to Practice before the U.S. Patent and Trademark Office

Education:

  • Juris Doctor, University of Dayton School of Law
  • Post-Doctoral Studies, Chemistry, University of Utah
  • Doctorate, Biochemistry, Medical College of Wisconsin
  • Bachelor of Science, Biochemistry, University of Illinois

Professional Affiliations:

  • American Intellectual Property Law Association
  • American Chemical Society
  • D.C. Science Writers Association
  • Editorial Advisory Board, Journal of Commercial Biotechnology

Representative Publications & Presentations:

  • Elizabeth Haanes, Benjamin L. Volk, Thomas J. Siepmann, “USPTO Publishes New (and Largely Improved) Guidance for Subject Matter Eligibility,” Dec. 16, 2014, Thompson Coburn, Internet
  • Zeynep Tokgöz, Thomas J. Siepmann, Frederick C., Streich, Jr., Brajesh Kumar, Jennifer M. Klein, and Arthur L. Haas, “E1-E2 Interactions In the Ubiquitin and Nedd8 Ligation Pathways: The E1β-Grasp Domain is an E2 Specificity Filter,” J. Biological Chemistry, 287(1):311-321, 2012.
  • Thomas J. Siepmann, “The Global Exportation of the Bayh-Dole Act,” 30 U. Dayton L. Rev. 209, 2004.
  • Thomas J. Siepmann, Richard N. Bohnsack, Zeynep Tokgöz, Olga V. Baboshina & Arthur L. Haas, “Protein Interactions Within the N-End Rule Ubiquitin Ligation Pathway,” J. Biological Chemistry, 278(11):9448-9457, 2003.
  • Olga V. Baboshina, Rita Crinelli, Thomas J. Siepmann & Arthur L. Haas, “N-End Rule Specificity Within the Ubiquitin/Proteasome Pathway is Not an Affinity Effect,” J. Biological Chemistry, 276(42):39428-39437, 2001.
  • Arthur L. Haas & Thomas J. Siepmann, “Pathways of Ubiquitin Conjugation,” FASEB J. 11(14):1257- 1268, 1997.